市場調查報告書
商品編碼
1368219
心導管電氣燒灼術設備的全球市場Global Cardiac Ablation Devices Market |
顛覆性技術推動創新
心律不整的增加和對微創治療的需求不斷增加正在推動心導管電氣燒灼術(CA)市場的成長。此外,與 CA 程序相關的風險較小,這使得它們在世界各地受到青睞。由於 COVID-19 大流行對非緊急(選擇性)醫療干涉措施的限制,2020 年和 2021 年全球對 CA 手術的需求有所下降。從2022年開始,疫情法規將放寬,全球CA程序積壓將導致CA設備市場成長激增。該市場包括CA系統、導管、發生器和其他產品領域。
CA 設備市場的參與企業已開始大力投資開發技術先進的解決方案,以快速、準確地治療心律不整,同時改善患者的治療效果。隨著與新興企業和技術供應商的合作不斷增加,CA設備市場已經擴大,產品系列包括心律不整診斷中的人工智慧、基於感測器的穿戴式設備、提高準確性的機器人、先進的繪圖系統、靈活的感測器晶片導管等。 .它以其先進的技術和解決方案獲得了巨大的關注。
微創心律不整治療的優惠報銷和保險政策的可用性可能會進一步支持 CA 手術的市場。在CA手術技術中,射頻消融儀佔全球CA市場佔有率的65%以上,但冷凍消融設備因其微創方法而迅速普及。冷凍消融技術的進步和對智慧冷凍消融設備不斷成長的需求正在導致這些創新技術的快速採用,從而在預測期內推動全球 CA 設備市場規模的成長。在亞太地區,基於球囊的冷凍消融和多電極冷凍消融是一些進步,導致更多地採用冷凍消融技術作為首選 CA 手術。
到 2022 年,美國基於導管的 CA 手術數量將超過心臟植入電子設備手術數量。過去年度,心臟 EP 手術在醫療保險中的比例顯著增加,這主要是由基於導管的 CA 手術推動的。近年來,基於心導管的肺靜脈隔離心房顫動治療的 EP 手術率急劇增加。冷凍消融術普及,因為它可用於心臟直視手術和微創手術,並且在多個病例中已被證明是有效和安全的。這一成長是由 CA 程序的有利報銷政策和亞太地區醫療旅遊業的成長所推動的。用於將冷凍消融與藥物療法或射頻消融相結合的混合方法的先進設備開發為患者提供了增強的、個體化的和更安全的治療選擇。
本研究報告分析了全球心導管電氣燒灼術設備市場,並提出了整體市場前景,包括按最終用戶、用途類型、設備類型和市場公司市場佔有率比例。宏觀經濟要素、最新趨勢、收益預測以及下一代 CA 技術和設備以及多個案例研究均已檢驗。研究期間為2021年至2027年,預測期間為2023年至2027年,以2022年為基準年。該研究重點關注顛覆性創新、未滿足的新市場以及不斷增加的心律不整患病,從而提供特定的市場成長機會。
Disruptive Technologies Drive Innovation
Rising incidents of cardiac arrhythmia and the increasing demand for minimally invasive procedures boost the cardiac ablation (CA) market growth. In addition, fewer risks associated with the CA procedure make it a preference, worldwide. Global demand for CA procedures declined in 2020 and 2021 due to the COVID-19 pandemic restrictions on non-emergency (elective) medical interventions. With the lessening of pandemic restrictions from 2022, the worldwide backlog of CA procedures surged the CA device market growth. The market includes product segments of CA systems, catheters, generators, and others.
CA device market participants started investing heavily in technologically advanced solution development to treat cardiac arrhythmias quickly and precisely, with improved patient outcomes. With more collaborations with start-ups and technology providers, the CA device market is witnessing huge traction with advanced technologies and solutions in the product portfolio, such as AI in arrhythmia diagnosis, sensor-based wearables, robotics for enhanced precision, advanced mapping system, and flexible sensor-tip catheters.
The availability of favorable reimbursement and insurance policies for minimally invasive cardiac arrhythmia treatments will further support the market for CA procedures. In CA procedure technology, although RF ablators dominate the global CA market with more than 65% of the market share, cryoablation devices are rapidly gaining adoption due to their minimally invasive approach. Advancements in cryoablation technology and the growing demand for smart cryoablation devices are rapidly leading to the surge in the adoption of these innovative technologies and bolstering the global CA device market size in the forecast period. In APAC, balloon-based cryoablation and multi-electrode cryoablation are some advancements leading to increased adoption of cryoablation technology as a preferred CA procedure.
In 2022, the frequency of catheter-based CA procedures exceeded the number of cardiac implantable electronic device procedures in the US and is expected to surge during the forecast period. Rates of cardiac EP procedures in Medicare have increased considerably over the last decade, majorly driven by catheter-based CA procedures. The ratio of cardiac catheter-based EP procedures for pulmonary vein isolation for treating AFib has witnessed a rapid rise over the last few years. The prevalence of cryoablation for cardiac arrhythmia treatment, as it can be used in both open-heart and minimally invasive procedures, has proven effectiveness and safety in several cases. This growth is bolstered by favorable reimbursement policies for CA procedures and the growth of the medical tourism industry in APAC. Advanced device development for usage in a hybrid approach by combining cryoablation with drug therapy or RF ablation offers patients enhanced, personalized, and safer treatment options.
This study analyzes the global cardiac ablation device market, including the entire market landscape by end-users, application types, device types, and market share percentage by market players. It examines macroeconomic factors, the latest trends, revenue forecasts, and next-generation CA technologies and devices, along with a few case studies. The study period is from 2021 to 2027, and the forecast period is from 2023 to 2027, with 2022 as the base year. The study provides specific market growth opportunities focusing on disruptive innovations, new unaddressed markets, increasing prevalence of cardiac arrhythmia, and others. The study concludes with the top 4 growth opportunities in the CA device market.